Stefan Sleijfer
Overview
Explore the profile of Stefan Sleijfer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
280
Citations
7901
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verschoor N, Bos M, Oomen-de Hoop E, Martens J, Sleijfer S, Jager A, et al.
Eur J Cancer
. 2024 Jun;
207:114159.
PMID: 38878446
Circulating tumor DNA (ctDNA) holds promise as a biomarker for guiding adjuvant treatment decisions in solid tumors. This review systematically assembles ongoing and published trials investigating ctDNA-directed adjuvant treatment strategies....
2.
Bos M, Kraan J, Starmans M, Helmijr J, Verschoor N, de Jonge M, et al.
Mol Oncol
. 2024 May;
18(11):2770-2782.
PMID: 38790134
Advances in therapeutic approaches for melanoma urge the need for biomarkers that can identify patients at risk for recurrence and to guide treatment. The potential use of liquid biopsies in...
3.
Verschoor N, Bos M, de Kruijff I, Van M, Kraan J, Drooger J, et al.
Breast Cancer Res Treat
. 2024 Jan;
205(1):87-95.
PMID: 38291268
Purpose: HER2 overexpressing circulating tumor cells (CTCs) are observed in up to 25% of HER2-negative metastatic breast cancer patients. Since targeted anti-HER2 therapy has drastically improved clinical outcomes of patients...
4.
Verschoor N, Smid M, Jager A, Sleijfer S, Wilting S, Martens J
Breast Cancer Res
. 2023 Nov;
25(1):145.
PMID: 37968696
Background: In breast cancer, the advent of anti-HER2 therapies has made HER2+ tumors a highly relevant subgroup. However, the exact characteristics which prohibit clinical response to anti-HER2 therapies and drive...
5.
Dane A, van Leeuwen R, Hoedemakers M, van der Kuy H, Sleijfer S
Front Pharmacol
. 2023 Sep;
14:1264951.
PMID: 37701038
Rapid increase in cost continues to have negative impact on patients' accessibility to life-changing anticancer medications. Moreover, the rising cost does not equate to similar increase in medication effectiveness. We...
6.
Angus L, Smid M, Wilting S, Bos M, Steeghs N, Konings I, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686693
Mutations in the estrogen receptor gene (), its transcriptional regulators, and the mitogen-activated protein kinase (MAPK) pathway are enriched in patients with endocrine-resistant metastatic breast cancer (MBC). Here, we integrated...
7.
Verschoor N, de Weerd V, Van M, Kraan J, Smid M, Heijns J, et al.
NPJ Breast Cancer
. 2023 Jul;
9(1):61.
PMID: 37452019
This prospective cohort study reports aneuploidy score by mFast-SeqS as a strong prognostic marker in MBC patients. mFAST-SeqS is an affordable and easily implementable method for the assessment of total...
8.
Brink P, Kalisvaart G, Schrage Y, Mohammadi M, IJzerman N, Bleckman R, et al.
Eur J Surg Oncol
. 2023 May;
49(9):106942.
PMID: 37246093
Background: The added value of local treatment in selected metastatic GIST patients is unclear. This study aims to provide insight into the usefulness of local treatment in metastatic GIST by...
9.
Schut A, de Bruin L, de Rooij B, Lidington E, Timbergen M, van der Graaf W, et al.
Cancer Med
. 2023 Apr;
12(12):13661-13674.
PMID: 37119048
Background: Desmoid-type fibromatosis (DTF) has a highly variable clinical course with varying intensity of symptoms. The objectives of this study were to identify subgroups of DTF patients based on physical...
10.
Bos M, Verhoeff S, Oosting S, Menke-van der Houven van Oordt W, Boers R, Boers J, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900167
According to the current guidelines, watchful waiting (WW) is a feasible option for patients with good or intermediate prognosis renal-cell carcinoma (RCC). However, some patients rapidly progress during WW, requiring...